Pharmacokinetic/pharmacodynamic modeling of rocuronium in myasthenic patients is improved by taking into account the number of unbound acetylcholine receptors

Anesthesia and Analgesia

Volumn 95, Issue 3, 2002, Pages 588-596

  De Haes, Ann ^a   Proost, Johannes H ^a   Kuks, Jan B M ^a   Van den Tol, David C ^a   Wierda, J Mark K H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; MIDAZOLAM; NITROUS OXIDE; OXYGEN; PHYSOSTIGMINE; PROPOFOL; ROCURONIUM; SUFENTANIL;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MYASTHENIA GRAVIS; NEUROMUSCULAR BLOCKING; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0036711939     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200209000-00018     Document Type: Article

References (31)

1. Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors
2. Anaesthesia and myasthenia gravis
3. Autoimmune diseases against cell surface receptors: Myasthenia gravis, a prototype anti-receptor disease
4. Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis
5. Rocuronium in the myasthenic patient
6. Vecuronium for muscle relaxation in patients with myasthenia gravis
7. Vecuronium dose-response and maintenance requirements in patients with myasthenia gravis
8. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
9. Mivacurium in the myasthenic patient
10. Sensitivity to vecuronium in myasthenia gravis: A dose-response study
11. Atracurium in myasthenics undergoing thymectomy
12. Vecuronium in the myasthenic patient
13. Neuromuscular monitoring at the orbicularis oculi may overestimate the blockade in myasthenic patients
14. A model, taking into account the number of unbound ACh-Receptors, improves the PK-PD analysis of rocuronium in myasthenic pigs
15. Clinical aspects
16. AAEE Minimonograph #33: Electrodiagnostic approach to defects of neuromuscular transmission
17. Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates
18. A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics
19. A comparison of a Bayesian population method with two methods as implemented in commercially available software
20. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations
21. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models
22. Atracurium-receptor kinetics: Simple behavior from a mixture
23. Mivacurium chloride and myasthenia gravis
24. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation
25. The margin of safety of neuromuscular transmission
26. Clinical use of atracurium in myasthenia gravis: A case report
27. The use of atracurium in Chinese myasthenic patients undergoing thymectomy
28. Evaluation of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich and sparse data
29. Evaluation of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data
30. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs
31. An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs